Management of Schizophrenia with Obsessive-Compulsive Features

Psychiatric Clinics of North America

Volumn 32, Issue 4, 2009, Pages 835-851

  Hwang, Michael Y ^a,b,c   Kim, Sung Wan ^a,d   Yum, Sun Young ^a,c,e   Opler, Lewis A ^a,f  

^a Franklin Delano Roosevelt Hospital   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c Janet Weis Children s Hospital   (United States)

^d Chonnam National University Medical School   (South Korea)

^e Lilly Pharmaceutical   (South Korea)

^f Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Amisulpride; Atypical antipsychotics; Comorbidity; Obsessive compulsive; Schizophrenia; SSRI

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; ESCITALOPRAM; FLUOXETINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; LITHIUM CARBONATE; LITHIUM SALT; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PROPRANOLOL; QUETIAPINE; QUINPIROLE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALPROIC ACID; ZIPRASIDONE;

ADJUVANT THERAPY; AKATHISIA; ANTICHOLINERGIC SYNDROME; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HEALTH STATUS; HUMAN; NEUROBIOLOGY; NEUROPSYCHOLOGY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PARANOID SCHIZOPHRENIA; PATHOGENESIS; PHARMACODYNAMICS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT;

ADULT; ANTIPSYCHOTIC AGENTS; CLINICAL PROTOCOLS; COGNITIVE THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 70450270895     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2009.08.002     Document Type: Review

References (83)

1. Hwang M.Y., Bermanzohn P.C., and Opler L.A. Obsessive-compulsive symptoms in patients with schizophrenia. In: Hwang M.Y., and Bermanzohn P.C. (Eds). Schizophrenia and comorbid conditions (2001), American Psychiatry Press, Washington (DC) 57-78
2. Kraemer H.C. DSM categories and dimensions in clinical and research contexts. In: Helzer J.E., Kraemer H.C., Krueger, et al. (Eds). Dimensional approaches in diagnostic classification: refining the research agenda for DSM-V (2008), American Psychiatric Press, Arlington (VA) 5-17
3. Westphal K. Ueber Zwangsvorstellungen (On compulsive thoughts). Arch Psychiatr Nervenkr 8 (1878) 734-750 [in German]
4. Kraepelin E. Dementia praecox, or the group of schizophrenias (1956), International University Press, NY
5. Stengel E. A study on some clinical aspects of the relationship between obsessional neurosis and psychotic reaction types. J Ment Sci 91 (1945) 166-184
6. Bleuler E. Dementia praecox, the group of schizophrenias (1956), International University Press, NY
7. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale for schizophrenia. Schizophr Bull 13 (1987) 261-276
8. Hwang M.Y., and Opler L.A. Schizophrenia with obsessive-compulsive features: assessment and treatment. Psychiatr Ann 24 (1994) 468-472
9. Hollander E. Obsessive-compulsive related disorders (1993), American Psychiatric Press, Washington (DC)
10. Eisen J., and Rasmussen S. Obsessive compulsive disorder with psychotic features. J Clin Psychiatry 54 (1993) 373-379
11. Thomsen P.H., and Jensen J. Obsessive-compulsive disorder: admission patterns and diagnostic stability. A case-register study. Acta Psychiatr Scand 90 (1994) 19-24
12. Jahrreiss W. Obsessions during schizophrenia. Arch Psychiatr Nervenkr 77 (1926) 740-788
13. Rosen I. The clinical significance of obsessions in schizophrenia. J Ment Sci 103 (1957) 778-785
14. Insel T.R., and Akiskal H.S. Obsessive-compulsive disorder with psychotic features: a phenomenological analysis. Am J Psychiatry 143 (1986) 1527-1533
15. Karno M., Golding J.M., Sorenson S.B., et al. The epidemiology of obsessive-compulsive disorder in five U.S. communities. Arch Gen Psychiatry 45 (1988) 1094-1099
16. Berman I., Kalinowski A., Berman S.M., et al. Obsessive and compulsive symptoms in chronic schizophrenia. Compr Psychiatry 36 (1995) 6-10
17. Hwang M.Y., Morgan J.E., and Losonczy M.F. Clinical and neuropsychological profiles of OC schizophrenia. J Neuropsychiatry Clin Neurosci 12 (2000) 91-94
18. Sevincok L., Akoglu A., and Kokcu F. Suicidality in schizophrenic patients with and without obsessive-compulsive disorder. Schizophr Res 90 (2007) 198-202
19. Buckley P.F., Miller B.J., Lehrer D.S., et al. Psychiatric comorbidities and schizophrenia. Schizophr Bull 35 (2009) 383-402
20. Poyurovsky M., and Koran L.M. Obsessive-compulsive disorder [OCD] with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications. J Psychiatr Res 39 (2005) 399-408
21. Poyurovsky M.D., Fuchs C., and Weizman A. Obsessive-compulsive disorder in patients with first-episode schizophrenia. Am J Psychiatry 156 (1999) 1998-2000
22. Craig T., Hwang M.Y., and Bromet E.J. Obsessive-compulsive and panic symptoms in patients with first-admission psychosis. Am J Psychiatry 159 (2002) 592-598
23. Rifkin J., Yucel M., Maruff P., et al. Psychiatric research. Neuroimaging 138 (2005) 99-113
24. Kim J.J., Youn T., Lee J.M., et al. Morphometric abnormality of the insula in schizophrenia: a comparison with obsessive-compulsive disorder and normal control using MRI. Schizophr Res 60 (2003) 191-198
25. Kwon J.S., Shin Y.W., Kim C.W., et al. Similarity and disparity of obsessive-compulsive disorder and schizophrenia in MR volumetric abnormalities of the hippocampus-amygdala complex. J Neurol Neurosurg Psychiatr 74 (2003) 962-964
26. Saxena S., and Rauch S.L. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am 23 (2000) 563-586
27. Hollander E., Braun A., and Simeon D. Should OCD leave the anxiety disorders in DSM-V? The case for obsessive compulsive-related disorders. Depress Anxiety 25 (2008) 317-329
28. Berman I., Merson A., Viegner B., et al. Obsessions and compulsions as a distinct cluster of symptoms in schizophrenia: a neuiropsychological study. J Nerv Ment Dis 186 (1998) 150-156
29. Lysaker P.H., Bryson G.J., Marks K.A., et al. Association of obsessions and compulsions in schizophrenia with neurocognition and negative symptoms. J Neuropsychiatry Clin Neurosci 14 (2002) 449-453
30. Lysaker P.H., Whitney K.A., and Davis L.W. Associations of executive function with concurrent and prospective reports of obsessive-compulsive symptoms in schizophrenia. J Neuropsychiatry Clin Neurosci 21 (2009) 38-42
31. Whitney K.A., Fastenau P.S., Evans J.D., et al. Comparative neuropsychological function in obsessive-compulsive disorder and schizophrenia with and without obsessive-compulsive symptoms. Schizophr Res 69 (2004) 75-83
32. Borkowska A., Pilaczyñska E., and Rybakowski J.K. The frontal lobe neuropsychological tests in patients with schizophrenia and/or obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 15 (2003) 359-362
33. Lichtenstein P., Yip B.H., Björk C., et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373 (2009) 234-239
34. Nestadt G., Samuels J., Riddle M.A., et al. The relationship between obsessive-compulsive disorder and anxiety and affective disorders: results from the Johns Hopkins OCD family study. Psychol Med 31 (2001) 481-487
35. Poyurovsky M., Kriss V., Weisman G., et al. Familial aggregation of schizophrenia-spectrum disorders and obsessive-compulsive associated disorders in schizophrenia probands with and without OCD. Am J Med Genet B Neuropsychiatr Genet 133B (2005) 31-36
36. Kwon JS, Joo YH, Nam HJ, et al. Association of the glutamate transporter gene SLC1A1 with atypical anitpsychotics-induced obsessive compulsive symptoms. Arch Gen Psychiatry, in press.
37. Bottas A., Cooke R.G., and Richter M.A. Comorbidity and pathophysiology of obsessive-compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia?. J Psychiatry Neurosci 30 (2005) 187-193
38. Iida J., Iwasaka H., Hirao F., et al. Clinical features of childhood-onset schizophrenia with obsessive-compulsive symptoms during the prodromal phase. Psychiatry Clin Neurosci 49 (1995) 201-207
39. Fenton W.S., and McGlashan T.H. The prognostic significance of obsessive compulsive symptoms in schizophrenia. Am J Psychiatry 143 (1986) 437-441
40. Khullar A., Chue P., and Tibbo P. Quetiapine and obsessive-compulsive symptoms [OCS]: case report and review of atypical antipsychoticinduced OCS. J Psychiatry Neurosci 26 (2001) 55-59
41. Alevizos B., Lykouras L., Zervas I.M., et al. Risperidone-induced obsessive-compulsive symptoms: a series of six cases. J Clin Psychopharmacol 22 (2002) 461-467
42. Lykouras L., Alevizos B., Michalopoulou P., et al. Obsessive-compulsive symptoms induced by atypical antipsychotics: a review of reported cases. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 333-346
43. Mouaffak F., Gallarda T., Bayle F.J., et al. Worsening of obsessive-compulsive symptoms after treatment with aripiprazole. J Clin Psychopharmacol 27 (2007) 237-238
44. Kim M., Park D.Y., Kwon J.S., et al. Prevalence and clinical characteristics of obsessive-compulsive symptoms associated with atypical antipsychotics. J Clin Psychopharmacol 27 (2007) 712-713
45. Kim S.W., Shin I.S., Kim J.M., et al. The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia. Clin Neuropharmacol 32 (2009) 224-226
46. Alevizos B., Papageorgiou C., and Christodoulou G.N. Obsessive-compulsive symptoms with olanzapine. Int J Neuropsychopharmacol 7 (2004) 375-377
47. Reznik I., Yavin I., Stryjer R., et al. Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study. Pharmacopsychiatry 37 (2004) 52-56
48. Metin O., Yazici K., Tot S., et al. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol 18 (2003) 463-467
49. Kim S.W., Shin I.S., Kim J.M., et al. Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study. J Clin Psychopharmacol 28 (2008) 349-352
50. Ramasubbu R., Ravindron A., and Lapierre Y. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. Pharmacopsychiatry 33 (2000) 236-238
51. Austin L.S., Lydiard R.B., Ballenger J.C., et al. Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biol Psychiatry 30 (1991) 225-232
52. 123I]{beta}-CIT SPECT. Am J Psychiatry 161 (2004) 2201-2206
53. 123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors. Neuropsychobiology 55 (2007) 156-162
54. Szechtman H., Sulis W., and Eilam D. Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessivecompulsive disorder (OCD). Behav Neurosci 112 (1998) 1475-1485
55. Glick I.D., Poyurovsky M., Ivanova O., et al. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. J Clin Psychiatry 69 (2008) 1856-1859
56. Kim S.W., Shin I.S., Kim J.M., et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol 32 (2009) 243-249
57. Hwang M.Y., Rho J., Opler L.A., et al. Treatment of obsessive-compulsive schizophrenic patient with clomipramine: clinical and neuropsychological findings. Neuropsychiatry Neuropsychol Behav Neurol 8 (1995) 231-233
58. Bloch M.H., Landeros-Weisenberger A., Kelmendi B., et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11 (2006) 622-632
59. Li X., May R.S., Tolbert L.C., et al. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry 66 (2005) 736-743
60. Allen L., and Tejera C. Treatment of clozapine induced obsessive-compulsive symptoms with sertraline. Am J Psychiatry 151 (1994) 1096-1097
61. Dodt J.E., Byerly M.J., Guadros C., et al. Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline. Am J Psychiatry 154 (1997) 582
62. Haddad P.M., and Sharma S.G. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21 (2007) 911-936
63. Stroebel C.F., and Szarek B.L. Use of clomipramine in treatment of obsessive-compulsive symptomatology. J Clin Psychopharmacol 4 (1984) 98-100
64. Berman I., Sapers B.L., Chang H.H., et al. Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine. J Clin Psychopharmacol 15 (1995) 206-210
65. Hwang M.Y., Martin A.M., Lindenmayer J.P., et al. Treatment of schizophrenia with obsessive-compulsive features with serotonin reuptake inhibitors. Am J Psychiatry 150 (1993) 1127
66. Poyurovsky M., Isakov V., Hromnikov S., et al. Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study. Int Clin Psychopharmacol 14 (1999) 95-100
67. Reznick I., and Sirota P. Obsessive-compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. J Clin Psychopharmacol 20 (2000) 410-416
68. Margetic B. Aggravation of schizophrenia by clomipramine in a patient with comorbid obsessive-compulsive disorder. Psychopharmacol Bull 41 (2008) 9-11
69. Bark N., and Lindenmayer J.P. Ineffectiveness of clomipramine for obsessive-compulsive symptoms in patients with schizophrenia. Am J Psychiatry 149 (1992) 136-137
70. Levin Z., and Hwang M.Y. Treatment of obsessive-compulsive schizophrenic patient with clomipramine. Neuropsychiatry, Neuropsychol Behav Neurol 9 (1996) 2
71. Spina E., and de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 100 (2007) 4-22
72. Centorrino F., Baldessarini R.J., Frankenburg F.R., et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 153 (1996) 820-822
73. Spina E., Avenoso A., Scordo M.G., et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 22 (2002) 419-423
74. Saito M., Yasui-Furukori N., Nakagami T., et al. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol 25 (2005) 527-532
75. Crewe H.K., Lennard M.S., Tucker G.T., et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 [CYP2D6] activity in human liver microsomes. Br J Clin Pharmacol 34 (1992) 262-265
76. Szegedi A., Anghelescu I., Wiesner J., et al. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32 (1999) 148-153
77. Hiemke C., Weigmann H., Härtter S., et al. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14 (1994) 279-281
78. Hiemke C., Peled A., Jabarin M., et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 22 (2002) 502-506
79. Weigmann H., Gerek S., Zeisig A., et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 23 (2001) 410-413
80. Kim S.W., Shin I.S., Kim J.M., et al. Factors potentiating the risk of mirtazapine-associated restless legs syndrome. Hum Psychopharmacol 23 (2008) 615-620
81. Hwang M.Y., and Opler L.A. Management of schizophrenia with obsessive-compulsive disorder. Psychiatr Ann 30 (2000) 23-28
82. Ekers D. Successful outcome of exposure and response prevention in the treatment of obsessive-compulsive disorder in patients with schizophrenia. Behavioral Cognitive Psychotherapy 32 (2004) 375-378
83. Green A.I., Canuso C.M., Brenner M.J., et al. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am 26 (2003) 115-139